Company intelligence / Profile preview

Hetero

Hyderabad, Telangana, India

Ownership: Private
Employees: ~22000
Development stage: Other

Overview

Hetero supplies over 40% of global anti-retroviral APIs and finished dosage forms for HIV/AIDS, is a major supplier for influenza (oseltamivir), and rapidly launched generic COVID-19 antivirals (remdesivir, favipiravir), maintaining approvals for global commercial supply and partnerships with organizations like Gilead Sciences and RDIF. The company is active in multiple therapeutic areas including oncology, cardiology, anti-infectives, and APIs for global pharma partners.[1][2][3][7][9]

Therapeutic areas: OncologyInfectious DiseasesEndocrinologyCardiovascular
Modalities: Small moleculeBiologicBiosimilarVaccine
Industry: Pharma

Drug pipeline

1 asset

dapoxetine (Azista Bhutan Healthcare)

Unknown

Partnerships

Gilead Sciences (remdesivir license)Russian Direct Investment Fund (Sputnik V vaccine manufacturing)

Beyond the preview

Go deeper on Hetero.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hetero.

Explore the full profile